A Setback In Its High-Profile “Nuc” Trial Creates An Overhang For Gilead’s HCV Pipeline
By
Joseph Haas / Email the Author / “The Pink Sheet” DAILY Feb. 17, 2012
Word Count: 1371 / Article # 14120217003
Executive Summary
Gilead concedes that 12 weeks of treatment with ribavirin and GS-7977, the high-profile “nuc” asset it obtained when it bought Pharmasset late in 2011 is suboptimal for genotype 1 null responders; general expectation is that longer duration of therapy might suffice.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.